A5087261151- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Virus-based gene therapy research
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Myeloid Leukemia Treatments
- Complement system in diseases
- Hemoglobinopathies and Related Disorders
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Iron Metabolism and Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hemostasis and retained surgical items
- Systemic Lupus Erythematosus Research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer-related gene regulation
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
Guy's and St Thomas' NHS Foundation Trust
2019-2022
St Thomas' Hospital
2021-2022
Royal Free London NHS Foundation Trust
2018
University College London
2015
The Royal Free Hospital
2015
Myeloproliferative neoplasms (MPN) are associated with an increased rate of venous thromboembolism (VTE), which is a major cause morbidity and mortality, especially in the more indolent diseases polycythaemia rubra vera (PV) essential thrombocythaemia (ET) (Pearson, 2002; Tefferi & Barbui, 2017). Multiple factors underlie complex pathogenesis thrombosis MPN including elevated blood viscosity, thrombocytosis leucocytosis. High levels inflammatory cytokines adhesion molecules, circulating...
Factor XI (FXI) concentrate is a pooled human plasma-derived factor used as replacement therapy for patients with FXI deficiency, which provides predictable response and consistent haemostatic cover in emergency or elective situations. It has previously been implicated adverse events such thrombosis inhibitor formation, rare case reports of fatal incidents. We sought to establish the incidence complications retrospective series between 1994 2012 at Haemophilia Comprehensive Care Centre Royal...